Equities

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)192.80
  • Today's Change-23.60 / -10.91%
  • Shares traded1.04m
  • 1 Year change+149.74%
  • Beta--
Data delayed at least 15 minutes, as of Oct 08 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The Company is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

  • Revenue in HKD (TTM)2.08bn
  • Net income in HKD-257.61m
  • Incorporated2016
  • Employees1.54k
  • Location
    Sichuan Kelun-Biotech Biopharmaceutical Co LtdNo. 666 Xinhua Avenue, Chengdu Cross-StrCHENGDU ChinaCHN
  • Websitehttp://www.kelun-biotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TYK Medicines Inc0.00-473.59m11.76bn144.00---------1.28-1.280.00-3.12---------------------------50.25-----100.00---22.97------
Keymed Biosciences Inc90.36m-822.34m13.11bn1.12k--4.49--145.03-3.15-3.150.345610.430.02070.31157.74100,739.50-18.86---20.96--68.65---909.38--4.83--0.2155--253.87---16.63------
Ascentage Pharma Group International999.36m-398.72m13.22bn574.00--15.56--13.23-1.38-1.383.442.700.29983.492.191,714,167.00-11.97-44.93-16.78-57.0496.9687.68-39.93-976.101.83-8.160.6865--5.85100.76-4.84--2.82--
InnoCare Pharma Ltd864.01m-521.12m14.99bn1.11k--1.72--17.35-0.3085-0.30850.51154.340.07860.98753.19793,397.30-4.88-13.41-6.20-15.3685.5985.99-62.04-172.163.77--0.1667--18.09240.3628.80--66.20--
RemeGen Co Ltd1.55bn-1.76bn17.91bn3.50k--4.01--11.59-3.27-3.272.875.420.24110.44136.06427,581.40-27.42-18.66-35.04-23.7577.1181.94-113.72-102.881.06-31.410.4737--40.16148.65-51.30--59.07--
Genscript Biotech Corp7.84bn-1.37bn30.91bn7.28k--3.27--3.94-0.6495-0.64953.714.440.30069.157.991,130,268.00-9.68-18.34-14.76-26.1553.6354.68-32.19-64.914.06--0.1972--34.1729.4457.91--17.14--
Sichuan Kelun-Biotech Biophrmctcl Co Ltd2.08bn-257.61m48.22bn1.54k--13.58--23.21-1.14-1.149.3915.940.58699.46167.741,468,051.00-7.28---16.56--61.81---12.40--5.59--0.0118--91.62--6.81------
Akeso Inc2.07bn-813.78m61.82bn2.82k--10.69--29.81-0.9687-0.96872.476.680.19250.37075.27746,602.30-8.18-11.59-9.19-13.8792.21---42.50-42.494.43-5.490.3922--440.35337.43273.60--63.99--
WuXi Biologics (Cayman) Inc18.94bn2.91bn94.93bn12.44k33.912.1119.005.010.67390.67394.4010.830.31635.352.981,486,838.005.578.286.8510.2538.6643.2517.6027.462.62--0.09280.0011.5646.38-23.0940.0720.32--
Data as of Oct 08 2024. Currency figures normalised to Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

6.63%Per cent of shares held by top holders
HolderShares% Held
RTW Investments LPas of 10 Jul 20231.93m1.49%
Wellington Management Co. LLPas of 30 Jun 20241.18m0.91%
Wellington Management Hong Kong Ltd.as of 27 Nov 20231.12m0.86%
China Universal Asset Management Co., Ltd.as of 10 Jul 20231.08m0.83%
Laurion Capital Management LPas of 10 Jul 2023939.60k0.72%
Fiera Capital (UK) Ltd.as of 31 Dec 2023658.10k0.51%
Norges Bank Investment Managementas of 31 Dec 2023635.40k0.49%
Fidelity Management & Research Co. LLCas of 30 Jun 2024397.54k0.31%
E Fund Management Co., Ltd.as of 31 Dec 2023347.50k0.27%
China Southern Asset Management Co., Ltd.as of 31 Dec 2023340.30k0.26%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.